

REFERENCES

1. Gilman, F.E., *Tabernaemontana divaricata*, Cooperative Extension Service Institute of Food and Agricultural Sciences, university of Florida, October, 1999.
2. van Beek, T.A., Verpoorte, R., Svendsen, A.B., Leeuwenberg, A.J., Bisset, N.G. (1984). *Tabernaemontana* L. (Apocynaceae): a review of its taxonomy, phytochemistry, ethnobotany and pharmacology. *Journal of Ethnopharmacology*, 10, 1-156.
3. Prachayasakul, W., Pongchaidecha, A., Chattipakorn, N., Chattipakorn, S. (2008). Ethnobotany & ethnopharmacology of *Tabernaemontana divaricata*, *Indian Journal of Medical Research*, 127, 317-335.
4. Henriques, A.T., Melo, A.A., Moreno, P.R., Ene, L.L., Henriques, J.A., Schapova, E.E. (1996). *Ervatamia coronaria*: chemical constituents and some pharmacological activities. *Journal of Ethnopharmacology*, 50, 19-25.
5. Kam, T.S, Loh, K.Y, Lim, L.H, Loong, W.L, Chuah, C.H, Wei, C. (1992). New alkaloids from the leaves of *Tabernaemontana divaricata*. *Tetrahedron Letters*, 33, 969-972.
6. Kam, T.S, Pang, H.S, Lim, T.M. (2003). Biologically active indole and bisindole alkaloids from *Tabernaemontana divaricata*. *Organic and Biomolecular Chemistry*, 1, 1292-1297.

7. Zhang, H., Wang, X.N., Lin, L.P., Ding, J., Yue, J.M. (2007). Indole Alkaloids from Three Species of the *Ervatamia* Genus: *E. officinalis*, *E. divaricata*, and *E. divaricata* Gouyahua. *Journal of Natural Products*, 70, 54-59.
8. Ingkaninan, K., Temkitthawon, P., Chuenchom, K., Yuyaem, T., Thongnoi, W. (2003). Screening for acetylcholinesterase inhibitory activity in plants used in Thai traditional rejuvenating and neurotonic remedies. *Journal of Ethnopharmacology*, 89, 261-264.
9. Ingkaninan, K., Changwijit, K., Suwanborirux, K. (2006). Vobasinyliboga bisindole alkaloids, potent acetylcholinesterase inhibitors from *Tabernaemontana divaricata* root. *Journal of Pharmacy and Pharmacology*, 58, 847-852.
10. Taesotikul, T., Panthon, A., Kanjanapoth, D., Verpoorte, R., Scheffer, J.J. (1989). Hippocratic screening of ethanolic extracts from two *Tabernaemontana* species. *Journal of Ethnopharmacology*, 27, 99-106.
11. Jennings, V., Gohla, S. (2001). Encapsulation of retinoids in solid lipid nanoparticles (SLN). *Journal of Microencapsulation*, 18(1), 149-158.
12. Wissing, S.A., Müller, R.H., (2001). A novel sunscreen system based on tocopherol acetate incorporated into solid lipid nanoparticles (SLN). *International Journal of Cosmetic Science*, 23, 233-243.
13. Wissing, S.A., Müller, R.H., (2001). Solid lipid nanoparticles (SLNTM)—a novel carrier for UV blockers. *Pharmazie*, 56, 783-786.

14. Souto, E.B., Wissing, S.A., Barbosa, C.M., Müller, R.H. (2004). Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. *International Journal of Pharmaceutics*, 278, 71–77.
15. Wissing, S.A., Lippacher, A., Müller, R.H., (2001). Investigations on the occlusive properties of solid lipid nanoparticles (SLNTM). *Journal of Cosmetic Science*, 52, 313–323.
16. Fantone, J.C., Ward, P.A. Repair, Inflammation. In: Rubin, E., eds. Essential pathology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2001: 23-46.
17. Mitchell, R.N., Cotran, R.S. Acute and chronic inflammation. In: Kumar, V., Cotran, R.S., Robbin, S.L., eds. Robbins basic pathology. 7th ed. Philadelphia: WB Saunders, 2003: 48-85.
18. Medzhitov, R. (2008). Origin and physiological roles of inflammation. *Nature*, 454, 428-435.
19. Khan, A.F., Khan F.M. (2010). Inflammation and acute phase response. *International Journal of Applied Biology and Pharmaceutical Technology*, 1(2), 312-321.
20. Collins, T. Acute and chronic inflammation. In: Cotran, R.S., Kumar, V., Collins, T., eds. Pathologic Basis of Disease. 6th ed. Philadelphia: WB Saunders Company, 1999: 50–88.

21. Chandrasoma, P., Taylor, C.R. Chronic inflammation. In: Chandrasoma, P., Taylor, C.R., eds. Concise pathology. 2nd ed. East Norwalk: Appleton & Lange, 1995: 69-77.
22. Ferguson, R. L. (2010). Chronic inflammation and mutagenesis. *Mutation Research*, 690, 3–11.
23. Bowman, W.C, Rand, D. The immune system and inflammatory mechanism. In: Immunosuppressant and anti-inflammatory drugs. Textbook of pharmacology. 2nd ed. London: Blackwell Scientific Publication, 1980: 13.1-13.35.
24. Larsen, G.L., Henson, P.M., (1983) Mediators of inflammation, *Annual Reviews of Immunology*, 1, 335-359.
25. White, M. (1999). Mediators of inflammation and the inflammation process. *Journal of Allergy Clinical Immunology*, 103(3), s378-381.
26. MacGlashan, D. (2003). Histamine: A mediator of inflammation. *Journal of Allergic Clinical Immunology*, s53-59.
27. Kumar, V., Abbas, A.K., Fausto, N., eds. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia: Elsevier Saunders, 2005: 69.
28. Cirino, G., Distrutti, E., Wallace, L.J. (2006). Nitric Oxide and Inflammation. *Inflammation & Allergy-Drug Targets*; 5, 115-119.
29. Closa, D., Folch-Puy, E. (2004). Oxygen Free Radicals and the Systemic Inflammatory Response. *Life*, 56(4): 185–191.

30. Borregaard, N., Cowland, J.B. (1997) Granules of the human neutrophilic polymorphonuclear leukocyte. *Blood*, 89, 3503–3521.
31. Salmon, J.A., Higgs, G.A. (1987) Prostaglandins and leukotrienes as inflammatory mediators. *British Medical Bulletin*, 43(2): 285-296.
32. Morrow, J.D, Ramwell, II L.J. Eicosanoids and platelet-activating factor. In: 54 Hardman, J.G., Limbird, L.E., editors. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw Hill, 2001: 669-680.
33. Tohda, C., Nakayama, N., Hatanaka, F., Komatsu, K. (2006). Comparison of Anti-inflammatory Activities of Six *Curcuma* Rhizomes: A Possible Curcuminoid-independent Pathway Mediated by *Curcuma phaeocaulis* Extract. *Evidence-based Complementary and Alternative Medicine*, 3(2), 255–260.
34. Procopiou, P.A., Biggadike, K., English, F.A., Farrel, R.M., et al. (2001) Novel glucocorticoid antedugs possessing a 17 β -(γ -lactone) ring. *Journal of Medicinal Chemistry*, 44, 602–612.
35. Young, J.M., Wagner, B.M., and Spires, D.A. (1983). Tachyphylaxis in 12-0-tetradecanoylphorbol acetate-and arachidonic-acid induced ear edema. *Journal of Investigative Dermatology*, 80, 48–52.
36. Young, J.M. and De Young, L.M. Cutaneous models of inflammation for the evaluation of topical and systemic pharmacological agents, in pharmacological Methods in the Control of Inflammation (Chang J.Y. and Lewis, A.J., eds.), A.R. Liss, New York, 1989; 215–231.

37. Young, J.M., Spires, D.A., Bedord, C.J., Wagner, B., Ballaron, S.J., and De Young, L.M. (1983). The mouse ear inflammatory response to topical arachidonic acid. *Journal of Investigative Dermatology*, 82: 367–371.
38. Gábor, M. (2003). Models of Acute Inflammation in the Ear. *Methods in Molecular Biology: Inflammation Protocols*, 225, 129-137.
39. Brattsand, R., Thalen, A., Roempke, K., Kallstrom, L., Gruvstad, E. (1982). Influence of 16 α , 17 α -acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids. *Journal of Steroid Biochemistry*, 16, 779–786.
40. Kuo, Y.C., Sun, C.M., Tsai, W.J., Ou, J.C., Chen, W.P., Lin, C.Y. (1999). Blocking of cell proliferation, cytokines production and genes expression following administration of chinese herbs in the human mesangial cells. *Life Science*, 64, 2089-2099.
41. Gupta, M., Mazumder, U.K, Kumar, R.S., Sivakumar, T., Gomathi, P. (2004). Antioxidant and protective effects of *Ervatamia coronaria* stape., leaves against carbon tetrachloride-induced liver injury. *European Bulletin of Drug Research*, 12, 13-22.
42. Melo, A.A., Querol, C.B., Henriques, A.T., Henriques, J.A. (1986). Cytostatic, cytotoxic and mutagenic effects of voacristine, an indole alkaloid in wild-type and repair-deficient yeasts. *Mutation Research*, 171, 17-24.
43. Müller, R.H., Mader, K. and Gohla, S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of art,

- European Journal of Pharmaceutics and Biopharmaceutics*, 50, 161-177.
44. Müller H.R., Radtke M., Wissing A.S. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. *Advanced Drug Delivery Reviews*, 54 Suppl.1, s131-s155.
 45. Wissing, A.S., Müller, H.R. (2003). Cosmetic applications for solid lipid nanoparticles (SLN). *International Journal of Pharmaceutics*, 254, 65–68.
 46. Tiyafoonchai, W., Tungpradit W., Plianbangchang, P. (2007) Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. *International Journal of Pharmaceutics*, 337, 299–306.
 47. Ma, Q.H., Xia, Q., Lu, Y.Y., Hao, X.Z., Gu, Ni., Lin, X.F., Luo, D. (2007) Preparation of tea polyphenols-loaded solid lipid nanoparticles based on the phase behaviors of hot microemulsions. *Solid State Phenomena*, 121-123, 705-708.
 48. ALHaj, A.N., Shamsudin, N.M., Alipiah, M.N., Zamri, F.H., Bustamam, A., Ibrahim, S., Abdullah, R. (2010) Characterization of *Nigella Sativa* L. Essential Oil-Loaded Solid Lipid Nanoparticles. *American Journal of Pharmacology and Toxicology*, 5(1), 52-57.
 49. Ansel, H.C., Popovich, N.G., Allen, L.V., eds. *Pharmaceutical Dosage Forms and Drug Delivery Systems*, 6th ed. Malvern, PA: Williams & Wilkins; 1995.

50. Aulton, M.E., ed. *Pharmaceutics: The Science of Dosage Form Design*. New York: Churchill Livingstone; 1988.
51. Vayalil, P.K., Elmets, C.A., Katiyar, S.K. (2003). Treatment of green tea polyphenols in hydrophilic cream prevents UVB-induced oxidation of lipids and proteins, depletion of antioxidant enzymes and phosphorylation of MAPK proteins in SKH-1 hairless mouse skin. *Journal of Carcinogenesis*, 24(5), 927-936.
52. Getie, M., Gebre-Mariam, T., Riety, R., Neubert, R.H. (2002). Evaluation of the release profiles of flavonoids from topical formulations of the crude extract of the leaves of *Dodonea viscosa* (Sapindaceae). *Pharmazie*, 57(5), 320-322.
53. Bernatoniene, J., Masteikova, R., Davalgienė, J., Peciura, R., Gauryliene, R., Bernatoniene, R., Majiene, D., Lazauskas, R., Civinskiene, G., Velziene, S., Muselik, J., Chalupova, Z. (2011). Topical application of *Calendula officinalis* (L.): Formulation and evaluation of hydrophilic cream with antioxidant activity. *Journal of Medicinal Plants Research*, 5(6), 868-877.
54. Mahmood, T., Akhtar, N., Khan, A.B., Ahmad, M., Khan, M.S.H., Zaman, U.S. (2010). Applications of a stable green tea extract cream on human cheeks. *International journal of academic research*, 2(2), 121-126.
55. Phutthawong, N., Jumpatong, K., Chairungsi, N., Wangkarn, S., Buddhasukh, D. (2007). Application of Electrocoagulation to the Isolation of Alkaloids. *Chiang Mai Journal of Science*, 34(1), 127-133.

56. Harborn, J.B. *Phytochemical Method: A Guide to Modern Technique of Plant Analysis*, Chapman and Hall, London, 1973: 229-302.
57. Stahl, E. *Thin-Layer Chromatography a laboratory handbook*, New York, 1965.
58. Kim, Y.S., Son, H.K., Chang, W.H., Kang, S.S., Kim, P.H. (1999). Inhibition of Mouse Ear Edema by Steroidal and Triterpenoid Saponins, *Archives of Pharmacal Research*, 22(3), 313-316.
59. Intahphuak, S., Khonsung, P., Panthong, A. (2010). Anti-inflammatory, analgesic, and antipyretic activities of virgin coconut oil. *Pharmaceutical Biology*, 48(2), 151–157.
60. Nualkaew, S., Rattanamanee, K., Thongpraditchote, S., Wongkrajang, Y., Nahrstedt, A. (2009). Anti-inflammatory, analgesic and wound healing activities of the leaves of *Memecylon edule* Roxb., *Journal of Ethnopharmacology*, 121, 278–281.
61. Wanikiat, P., Panthong, A., Sujayanon, P., Yoosook, C., Rossi, G.A., Reutrakul, V. (2008). The anti-inflammatory effects and the inhibition of neutrophil responsiveness by *Barleria lupulina* and *Clinacanthus nutans* extracts, *Journal of Ethnopharmacology*, 116, 234–244.
62. Draize, J.H. *Dermal Toxicity. Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics*. Association of Food and Drug Officials of the United States, 1959: 46–59.

63. Thomas, M.J. and Majors, P.A. (1973). Animal, Human, and Microbiological Safety Testing of Cosmetic Product. *Journal of the Society of Cosmetic Chemists*, 24, 135-146.
64. Kojic, Z., Stojanovic, D., Popadic, S., Jokanovic, M., Janackovic, D. (2009). The irritative property of α -tricalcium phosphate to the rabbit skin, *General Physiology and Biophysics*, Special Issue, 28, 168–173.
65. Vivek, K., H. Reddy, R.S.R. Murthy. (2007). Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. *AAPS PharmSciTech*. 8(4), 16-24.
66. Müller-Goymann, C.C., (2004). Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. *European Journal of Pharmaceutics and Biopharmaceutics*, 58(2), 343-356.
67. Ruktanonchai, U., Limpakdee, S., Meejoo, S., Sakulkhu, U., et al. (2008). The effect of cetyl palmitate crystallinity on physical properties of gamma-oryzanol encapsulated in solid lipid nanoparticles. *Nanotechnology*. 19, 095701.
68. Heurtault, B., Saulnier, P., Pech, B., Proust, J-E., Benoit, J-P. (2003). Physico-chemical stability of colloidal lipid particles. *Biomaterials*. 24(23), 4283-4300.